5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Successful use of fenfluramine as an add-on treatment for Dravet syndrome.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite the development of new antiepileptic drugs, Dravet syndrome frequently remains therapy resistant and is a catastrophic epilepsy syndrome. Fenfluramine is an amphetamine-like drug that has been used in the past as a part of antiobesity treatments. Because of the possible cardiac adverse effects (valve thickening, pulmonary hypertension) associated with use of fenfluramine, it was withdrawn from the market in 2001. In Belgium, a Royal Decree permitted examination of the potential anticonvulsive effects of fenfluramine in a clinical trial consisting of a small group of patients diagnosed with Dravet syndrome.

          Related collections

          Author and article information

          Journal
          Epilepsia
          Epilepsia
          1528-1167
          0013-9580
          Jul 2012
          : 53
          : 7
          Affiliations
          [1 ] Department of Neurology-Pediatric Neurology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium. berten.ceulemans@uza.be
          Article
          10.1111/j.1528-1167.2012.03495.x
          22554283
          03a22d2e-e53b-4bb9-a344-2b3e88a4999b
          Wiley Periodicals, Inc. © 2012 International League Against Epilepsy.
          History

          Comments

          Comment on this article